10-99727098-G-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_078470.6(COX15):c.452C>G(p.Ser151Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.00033 in 1,614,074 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00028 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00034 ( 0 hom. )
Consequence
COX15
NM_078470.6 stop_gained
NM_078470.6 stop_gained
Scores
4
2
1
Clinical Significance
Conservation
PhyloP100: 5.77
Genes affected
COX15 (HGNC:2263): (cytochrome c oxidase assembly homolog COX15) Cytochrome c oxidase (COX), the terminal component of the mitochondrial respiratory chain, catalyzes the electron transfer from reduced cytochrome c to oxygen. This component is a heteromeric complex consisting of 3 catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The mitochondrially-encoded subunits function in electron transfer, and the nuclear-encoded subunits may function in the regulation and assembly of the complex. This nuclear gene encodes a protein which is not a structural subunit, but may be essential for the biogenesis of COX formation and may function in the hydroxylation of heme O, according to the yeast mutant studies. This protein is predicted to contain 5 transmembrane domains localized in the mitochondrial inner membrane. Alternative splicing of this gene generates two transcript variants diverging in the 3' region. [provided by RefSeq, Jul 2008]
CUTC (HGNC:24271): (cutC copper transporter) Members of the CUT family of copper transporters are associated with copper homeostasis and are involved in the uptake, storage, delivery, and efflux of copper (Gupta et al., 1995 [PubMed 7635807]; Li et al., 2005 [PubMed 16182249]).[supplied by OMIM, Mar 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 10-99727098-G-C is Pathogenic according to our data. Variant chr10-99727098-G-C is described in ClinVar as [Pathogenic]. Clinvar id is 496238.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr10-99727098-G-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COX15 | NM_078470.6 | c.452C>G | p.Ser151Ter | stop_gained | 4/9 | ENST00000016171.6 | NP_510870.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COX15 | ENST00000016171.6 | c.452C>G | p.Ser151Ter | stop_gained | 4/9 | 1 | NM_078470.6 | ENSP00000016171 | P1 | |
COX15 | ENST00000370483.9 | c.452C>G | p.Ser151Ter | stop_gained | 4/9 | 1 | ENSP00000359514 | |||
CUTC | ENST00000493385.5 | n.309+3988G>C | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.000283 AC: 43AN: 152196Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
43
AN:
152196
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000251 AC: 63AN: 251470Hom.: 0 AF XY: 0.000272 AC XY: 37AN XY: 135912
GnomAD3 exomes
AF:
AC:
63
AN:
251470
Hom.:
AF XY:
AC XY:
37
AN XY:
135912
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000335 AC: 490AN: 1461878Hom.: 0 Cov.: 34 AF XY: 0.000336 AC XY: 244AN XY: 727238
GnomAD4 exome
AF:
AC:
490
AN:
1461878
Hom.:
Cov.:
34
AF XY:
AC XY:
244
AN XY:
727238
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000283 AC: 43AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.000309 AC XY: 23AN XY: 74348
GnomAD4 genome
AF:
AC:
43
AN:
152196
Hom.:
Cov.:
32
AF XY:
AC XY:
23
AN XY:
74348
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
2
ALSPAC
AF:
AC:
4
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
27
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 10, 2024 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 21412973, 22310368, 33171185, 32232962, 31345219, 15863660, 33746038) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change creates a premature translational stop signal (p.Ser151*) in the COX15 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in COX15 are known to be pathogenic (PMID: 15863660, 21412973). This variant is present in population databases (rs149718203, gnomAD 0.05%). This premature translational stop signal has been observed in individual(s) with mitochondrial complex IV deficiency (PMID: 15863660, 21412973, 33746038). This variant is also known as 503C>G (H152X). ClinVar contains an entry for this variant (Variation ID: 496238). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
COX15-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 28, 2024 | The COX15 c.452C>G variant is predicted to result in premature protein termination (p.Ser151*). This variant has been reported in the compound heterozygous state in individuals with COX15-related disease (Bugiani et al. 2005. PubMed ID: 15863660; Alfadhel et al. 2011. PubMed ID: 21412973; Galvão de Oliveira et al. 2021. PubMed ID: 33746038). This variant is reported in 0.051% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in COX15 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Dec 07, 2020 | ACMG classification criteria: PVS1, PS4, PM2, PM3 - |
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2011 | - - |
Leigh syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 09, 2022 | Variant summary: COX15 c.452C>G (p.Ser151X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 0.00025 in 251510 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in COX15 causing Leigh Syndrome (0.00025 vs 0.0013), allowing no conclusion about variant significance. c.452C>G has been reported in the literature in individuals affected with Leigh Syndrome and subsequently cited by others (example, Bugiani_2005, Invernizzi_2012, Alfadhel_2011, Halperin_2020, Miryounesi_2016, de Oliveira_2021). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of normal complex IV activity in patient derived muscle and fibroblast samples (Bugiani 2005, Alfadhel 2011). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
A;A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at